Hyperlipoproteinemia Type II
"Hyperlipoproteinemia Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Descriptor ID |
D006938
|
| MeSH Number(s) |
C16.320.565.398.481 C18.452.584.500.500.644.475 C18.452.648.398.481
|
| Concept/Terms |
Hyperlipoproteinemia Type II- Hyperlipoproteinemia Type II
- Hyperlipoproteinemia Type IIs
- Hyper-Low Density Lipoproteinemia
- Density Lipoproteinemia, Hyper-Low
- Density Lipoproteinemias, Hyper-Low
- Hyper Low Density Lipoproteinemia
- Hyper-Low Density Lipoproteinemias
- Lipoproteinemia, Hyper-Low Density
- Lipoproteinemias, Hyper-Low Density
- Hyper-Low-Density-Lipoproteinemia
- Hyper-Low-Density-Lipoproteinemias
- Hyperlipoproteinemia, Type II
- Hyperlipoproteinemias, Type II
- Type II Hyperlipoproteinemia
- Type II Hyperlipoproteinemias
- Hypercholesterolemia, Essential
- Essential Hypercholesterolemia
- Essential Hypercholesterolemias
- Hypercholesterolemias, Essential
- Hypercholesterolemia, Familial
- Familial Hypercholesterolemia
- Familial Hypercholesterolemias
- Hypercholesterolemias, Familial
- Hypercholesterolemic Xanthomatosis, Familial
- Familial Hypercholesterolemic Xanthomatoses
- Familial Hypercholesterolemic Xanthomatosis
- Hypercholesterolemic Xanthomatoses, Familial
- Xanthomatoses, Familial Hypercholesterolemic
- Xanthomatosis, Familial Hypercholesterolemic
- Hyperlipoproteinemia Type 2
- Hyperlipoproteinemia Type 2s
- Type 2, Hyperlipoproteinemia
- Hyper-beta-Lipoproteinemia
- Hyper beta Lipoproteinemia
- Hyper-beta-Lipoproteinemias
- Hyperbetalipoproteinemia
- Hyperbetalipoproteinemias
Hyperlipoproteinemia Type IIb- Hyperlipoproteinemia Type IIb
- Hyperlipoproteinemia Type IIbs
- Hypercholesterolemia, Autosomal Dominant, Type B
- Familial Combined Hyperlipoproteinemia
- Combined Hyperlipoproteinemia, Familial
- Combined Hyperlipoproteinemias, Familial
- Familial Combined Hyperlipoproteinemias
- Hyperlipoproteinemia, Familial Combined
- Hyperlipoproteinemias, Familial Combined
- Apolipoprotein B-100, Familial Defective
- Apolipoprotein B 100, Familial Defective
- Apolipoprotein B-100, Familial Ligand-Defective
- Apolipoprotein B 100, Familial Ligand Defective
Hyperlipoproteinemia Type IIa- Hyperlipoproteinemia Type IIa
- Hyperlipoproteinemia Type IIas
- Hyperlipoproteinemia, Type IIa
- Hyperlipoproteinemias, Type IIa
- Type IIa Hyperlipoproteinemia
- Type IIa Hyperlipoproteinemias
- Hypercholesterolemia, Autosomal Dominant
- Autosomal Dominant Hypercholesterolemia
- Autosomal Dominant Hypercholesterolemias
- Dominant Hypercholesterolemia, Autosomal
- Dominant Hypercholesterolemias, Autosomal
- Hypercholesterolemias, Autosomal Dominant
- LDL Receptor Disorder
- Disorder, LDL Receptor
- Disorders, LDL Receptor
- LDL Receptor Disorders
- Receptor Disorder, LDL
- Receptor Disorders, LDL
|
Below are MeSH descriptors whose meaning is more general than "Hyperlipoproteinemia Type II".
Below are MeSH descriptors whose meaning is more specific than "Hyperlipoproteinemia Type II".
This graph shows the total number of publications written about "Hyperlipoproteinemia Type II" by people in this website by year, and whether "Hyperlipoproteinemia Type II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2016 | 1 | 1 | 2 |
| 2017 | 20 | 1 | 21 |
| 2018 | 24 | 1 | 25 |
| 2019 | 2 | 0 | 2 |
| 2020 | 4 | 0 | 4 |
| 2021 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Hyperlipoproteinemia Type II" by people in Profiles.
-
Mucormycosis and glucose-regulated protein 78 in COVID-19: Amenable to statin treatment? J Intern Med. 2021 10; 290(4):931-933.
-
Older Familial Hypercholesterolemia Patients with COVID-19. Gerontology. 2021; 67(5):608-610.
-
Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19. J Clin Lipidol. 2021 Mar-Apr; 15(2):379-380.
-
Collateral damage of the COVID-19 pandemic on the management of homozygous familial hypercholesterolemia. J Clin Lipidol. 2021 Mar-Apr; 15(2):381-382.
-
Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment. Atherosclerosis. 2021 03; 320:53-60.
-
PCSK9 inhibitors for COVID-19: an opportunity to enhance the antiviral action of interferon in patients with hypercholesterolaemia. J Intern Med. 2021 05; 289(5):749-751.
-
Familial hypercholesterolaemia and cascade testing in general practice: Lessons from COVID-19. Aust J Gen Pract. 2020 Dec; 49(12):859-860.
-
Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia. J Clin Lipidol. 2020 Nov - Dec; 14(6):751-755.
-
The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia. Curr Atheroscler Rep. 2020 09 01; 22(11):64.
-
Prevention of endothelial dysfunction and thrombotic events in COVID-19 patients with familial hypercholesterolemia. J Clin Lipidol. 2020 Sep - Oct; 14(5):617-618.